Dolly A. Vance

2020

In 2020, Dolly A. Vance earned a total compensation of $1.2M as Executive Vice President, Corporate Affairs, General at Rigel Pharmaceuticals, a 1% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$200,770
Option Awards$459,869
Salary$524,890
Other$9,054
Total$1,194,583

Vance received $524.9K in salary, accounting for 44% of the total pay in 2020.

Vance also received $200.8K in non-equity incentive plan, $459.9K in option awards and $9.1K in other compensation.

Rankings

In 2020, Dolly A. Vance's compensation ranked 7,856th out of 13,090 executives tracked by ExecPay. In other words, Vance earned more than 40.0% of executives.

ClassificationRankingPercentile
All
7,856
out of 13,090
40th
Division
Manufacturing
3,323
out of 5,621
41st
Major group
Chemicals And Allied Products
1,347
out of 2,254
40th
Industry group
Drugs
1,169
out of 1,954
40th
Industry
Pharmaceutical Preparations
871
out of 1,459
40th
Source: SEC filing on April 6, 2021.

Vance's colleagues

We found four more compensation records of executives who worked with Dolly A. Vance at Rigel Pharmaceuticals in 2020.

2020

Raul Rodriguez

Rigel Pharmaceuticals

Chief Executive Officer

2020

Dean Schorno

Rigel Pharmaceuticals

Chief Financial Officer

2020

David Santos

Rigel Pharmaceuticals

Executive Vice President and Chief Commercial Officer

2020

Wolfgang Dummer

Rigel Pharmaceuticals

Chief Medical Officer

News

You may also like